Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Scientists map how cinnamon’s bioactives interact with cancer signaling

15

Dec 2025

Scientists map how cinnamon’s bioactives interact with cancer signaling

This review synthesizes preclinical evidence showing that cinnamon-derived compounds can modulate inflammation, oxidative stress, apoptosis, and angiogenesis through multiple cancer-related signaling pathways. While biologically plausible, the findings are largely limited to cell and animal models, underscoring the need for pharmacokinetic, safety, and clinical validation.

Indoor tanning loads normal skin with mutations linked to melanoma

15

Dec 2025

Indoor tanning loads normal skin with mutations linked to melanoma

Indoor tanning is associated with markedly higher mutation burdens and cancer-driving genetic changes in melanocytes taken from normal-appearing skin, including areas usually protected from sunlight. These molecular alterations provide a biological explanation for the higher odds of melanoma and multiple primary tumors seen in heavy tanning bed users.

Gut bacteria patterns differ in autism and siblings and link to social symptoms

15

Dec 2025

Gut bacteria patterns differ in autism and siblings and link to social symptoms

This sibling-controlled East Asian study found that autistic individuals, their unaffected siblings, and typically developing controls differ in gut microbiota diversity and composition, with the clearest separation between autism and typical development. Specific taxa, particularly the butyrate-producing genus Anaerostipes, were modestly associated with social communication and internalising symptoms, supporting a gut–behaviour link without implying causality.

New initiative aims to transform care for early-onset cancer patients

15

Dec 2025

New initiative aims to transform care for early-onset cancer patients

More people under age 50 are developing cancer, and with that comes a shift in the model of care needed to serve this unique cancer patient population – including early access to fertility counseling, universal genomic testing to identify underlying genetic drivers, support resources to address long-term survivorship considerations, and community education regarding early detection and screening.

Chemotherapy may reduce HIV-infected T cells

15

Dec 2025

Chemotherapy may reduce HIV-infected T cells

Advancements in HIV/AIDS research, drug development and clinical practice since the 1980s have made it possible for people living with HIV to lead long, productive lives and keep the virus in check at undetectable levels and nontransmissible as long as therapy is maintained.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.